<DOC>
	<DOCNO>NCT02714322</DOCNO>
	<brief_summary>To assess equivalence MYL-1401A Humira® regard efficacy subject moderate-to-severe chronic plaque psoriasis</brief_summary>
	<brief_title>MYL-1401A Efficacy Safety Comparability Study Humira®</brief_title>
	<detailed_description>Eligible subject randomly assign base predefined stratification factor weight , geographic region , presence psoriatic arthritis : Randomization 2:1 MYL-1401A Humira® , respectively . The study conduct outpatient setting comprise 3 period : screening period 4 week , 52-week treatment period , safety follow-up 8 week . A subject consider complete study complete 52-week treatment period 8-week follow-up visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subject sign informed consent form 2 . Subject age 18 75 year , inclusive , time Screening 3 . Subject moderatetosevere chronic plaque psoriasis least 6 month Subject involve BSA ≥10 % , PASI ≥12 , sPGA ≥3 ( moderate ) Screening Baseline 4 . Subject stable disease least 2 month ( i.e . without significant change define investigator ) 5 . Subject candidate systemic therapy 6 . Subject previous failure , inadequate response , intolerance , contraindication least 1 conventional antipsoriatic systemic therapy 7 . Subject naïve adalimumab therapy , approve investigational 8 . For female childbearing potential , negative serum pregnancy test Screening negative urine pregnancy test Baseline 1 . Subject diagnosed erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis , skin condition ( e.g . eczema ) , systemic autoimmune disorder inflammatory disease time screen visit would interfere evaluation effect study treatment psoriasis 2 . Subject use follow medication within specified time period require use study : Topical medication within 2 week end screen period oral psoralen ultraviolet A ( PUVA ) phototherapy and/or ultraviolet B ( UVB ) phototherapy within 4 week end screen period Nonbiologic systemic therapy within 4 week end screen period ( e.g . cyclosporine , methotrexate , acitretin ) Any prior concomitant adalimumab therapy , approve investigational Any investigational agent within 90 day 5 halflives Screening ( whichever longer ) Any systemic steroid 4 week end screen period Note : Lowpotency topical corticosteroid apply palm , sol , face , intertriginous area permit study participation 3 . Subject receive live vaccine 4 week prior Screening intention receive live vaccine time study 4 . Subject positive test tuberculosis ( TB ) Screening know history active latent TB , except documented complete adequate treatment TB initiation ( &gt; 1 month ) adequate prophylaxis latent TB , isoniazidbased regimen Subjects positive purify protein derivative ( PPD ) history Bacillus CalmetteGuérin vaccination allow negative Interferonγ release assay ( IGRA ) Subjects positive PPD test without history Bacillus CalmetteGuérin vaccination subject positive indeterminate IGRA allow follow : No symptom sign active TB , include negative chest xray within 3 month prior first dose study treatment Documented history completion adequate treatment TB initiation ( &gt; 1 month ) adequate prophylaxis latent TB , isoniazidbased regimen prior receive study treatment accordance local recommendation 5 . Underlying condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious , gastrointestinal ) , opinion investigator , significantly immunocompromises subject and/or place subject unacceptable risk receive immunomodulatory therapy 6 . Subject plan surgical intervention duration study except related underlying disease , opinion investigator , put subject risk hinder subject 's ability maintain compliance study treatment visit schedule 7 . Subject active serious infection history infection follow : Any active infection : For nonsystemic antiinfectives use within 4 week prior randomization . Requiring hospitalization systemic antiinfectives within 8 week prior randomization Recurrent chronic infection active infection , opinion investigator , might cause study detrimental subject Invasive fungal infection mycobacterial infection Opportunistic infection , listeriosis , legionellosis , pneumocystis 8 . Subject positive human immunodeficiency virus , hepatitis C virus antibody hepatitis B surface antigen ( HBsAg ) positive hepatitis B core antibody negative HBsAg Screening 9 . Subject history clinically significant hematological abnormality , include cytopenia ( e.g . thrombocytopenia , leukopenia ) 10 . Subject severe progressive uncontrolled , clinically significant disease judgment investigator render subject unsuitable study 11 . Subject history malignancy within 5 year except adequately treat cutaneous squamous basal cell carcinoma , situ cervical cancer situ breast ductal carcinoma 12 . Subject active neurological disease multiple sclerosis , GuillainBarré syndrome , optic neuritis , transverse myelitis , history neurologic symptom suggestive central nervous system demyelinate disease 13 . Subject moderatetosevere heart failure ( New York Heart Association class III/IV ) 14 . Subject history hypersensitivity active substance excipients Humira® MYL1401A 15 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation 16 . Evidence alcohol drug abuse dependency time Screening , 5 year prior Screening study 17 . Subject unable follow study instruction comply protocol opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Biologics</keyword>
	<keyword>Biosimilar</keyword>
</DOC>